Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2012

View Archived Issues

Herbal flavonoid counteracts alcohol intoxication

Inverseon announces initial indication for INV-102

Researchers at Sanofi prepare novel endothelial lipase inhibitors

Sumagen set to start phase I testing of new HIV vaccine

Merck & Co. presents new GPR119 receptor agonists

Novel insulin-like growth factor 1 receptor antagonists patented by Novartis

Novel muscarinic acetylcholine M1 receptor positive allosteric modulators claimed

Abbott prepares new cannabinoid CB2 receptor ligands

U.S. team reports new method to stabilize proteins for therapeutic use

Boehringer Ingelheim and Vitae Pharmaceuticals patent new 11-beta-HSD1 inhibitors

MediciNova and University of Colorado Boulder collaborate on post-TBI therapy

Pergamum begins phase II DPK-060 trial in outer ear infections

Canadian study finds protein kinase inhibitors have potential to reverse resistance to antibiotics

Omni Bio plans new clinical studies of alpha-1-antitrypsin

DAPTA analogue reduces neuropathic pain in animal models

Vernalis and Servier establish new oncology collaboration

Additional funds support IDRI's work in tuberculosis

Evotec and Harvard University form new alliance

Xenetic Biosciences updates status of SymbioTec acquisition and SIIL arrangements

Idenix launches phase I/II IDX-719 study

Phase III study of elacytarabine delayed by manufacturing issues

LoneStar Heart acquires exclusive worldwide license

Ventana to develop companion diagnostic test for Bayer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...